DOCSLIB.ORG

Naropin 2Mg/Ml with Fentanyl 2Microgram/Ml Solution for Infusion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Naropin 2Mg/Ml with Fentanyl 2Microgram/Ml Solution for Infusion NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAROPIN 2 mg/mL WITH FENTANYL 2 microgram/mL (ropivacaine hydrochloride plus fentanyl citrate) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for infusion contains ropivacaine hydrochloride 2mg and fentanyl citrate 2microgram. For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM NAROPIN WITH FENTANYL is a sterile, isotonic solution with nominal osmolality of 288 mOsmol/kg and pH of 4.0 – 6.0. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Acute Pain Management: Continuous epidural infusion e.g. postoperative or labour pain. 4.2 Dose and method of administration Tolerability varies between patients. The lowest dosage that results in effective analgesia should be used and should be based on the status of the patient and the analgesia required. Careful observation of the patient must be maintained during the infusion. Adults Recommended doses for NAROPIN WITH FENTANYL for injection in the average healthy 70 kg adult for up to 72 hours. Epidural administration Continuous infusion Volume Dosage mL/hour Ropivacaine Fentanyl Naropin 2 mg/mL + Fentanyl 2 microgram/mL 6-14 12-28 mg/hr 12-28 microgram/ hr Children Until further experience has been gained, NAROPIN WITH FENTANYL cannot be recommended for use in children below the age of 12 years. Elderly or debilitated patients Debilitated or elderly patients, including those with partial or complete heart conduction block, advanced liver disease or severe renal dysfunction should be given reduced dosage commensurate with their physical condition. Clinical studies with this group of patients have not been performed. (See section 4.4). NAROPIN WITH FENTANYL Data Sheet 2 Test Dose For epidural analgesia, a 3-5 mL test dose of a local anaesthetic, preferably containing up to 5 microgram of adrenaline (e.g. Xylocaine 2% with Adrenaline 1:200,000), should be administered. Verbal contact and repeated monitoring of the heart rate and blood pressure should be maintained for 5 minutes following the test dose after which, in the absence of signs of intravascular or intrathecal injection, the main dose may be administered. An inadvertent intravascular injection may be recognised by a temporary increase in heart rate and an accidental intrathecal injection by signs of a spinal block. If toxic symptoms or signs occur, the infusion should be stopped immediately. Analgesia When calculating the dosage for postoperative analgesia, the use of intraoperative local anaesthetics and opioids should be taken into account. When prolonged blocks are used, either by continuous infusion or repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Cumulative doses of up to 800 mg ropivacaine for surgery and postoperative analgesia administered over 24 hours were well tolerated, as were postoperative continuous epidural infusions of ropivacaine with 2 microgram fentanyl at rates up to 14 mL/hour for 72 hours. 4.3 Contraindications 1. Hypersensitivity NAROPIN WITH FENTANYL solutions are contraindicated in patients with known hypersensitivity to local anaesthetics of the amide type or a known intolerance to fentanyl. 2. Bronchial asthma. See also section 4.4. 3. Head injuries and increased intracranial pressure – As for any opioid analgesic, fentanyl should not be used in patients susceptible to respiratory depression, such as comatose patients who may have head injuries or a brain tumour. Fentanyl may obscure the clinical course of patients with head injury. 4. Concomitant MAO Inhibitors Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics and the use of fentanyl in patients who have received MAO inhibitors within 14 days is not recommended. (See section 4.5). 5. Myasthenia gravis Fentanyl may cause muscle rigidity upon IV administration. Therefore, the need for reversal and muscle relaxants contraindicates its use in patients with a history of myasthenia gravis. 4.4 Special warnings and precautions for use Regional anaesthetic procedures should always be performed in a properly equipped and staffed area. Equipment and medicines necessary for monitoring and emergency resuscitation should be immediately available. Patients receiving major blocks should have an IV line inserted before the blocking procedure. The clinician responsible should be appropriately trained and familiar with diagnosis and treatment of side effects, systemic toxicity and other complications. (See section 4.9). NAROPIN AND FENTANYL Data Sheet Copyright 3 Patients in poor general condition due to ageing or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anaesthesia is frequently the optimal anaesthetic technique in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimise the patient’s condition before major blocks are performed, and the dosage should be adjusted accordingly. Patients treated with anti- arrhythmic drugs class III (e.g. amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive. There have been rare reports of cardiac arrest during the use of NAROPIN for epidural anaesthesia of peripheral nerve blockade, especially after unintentional accidental intravascular administration in elderly patients and in patients with concomitant heart disease. In some instances, resuscitation has been difficult. Should cardiac arrest occur, prolonged resuscitative efforts may be required to improve the possibility of a successful outcome. NAROPIN is metabolised in the liver and should therefore be used with caution in patients with severe liver disease and repeated doses may need to be reduced due to delayed elimination. Normally there is no need to modify the dose in patients with impaired renal function when used for single dose or short term treatment. Acidosis and reduced plasma protein concentration, frequently seen in patients with chronic renal failure may increase the risk of systemic toxicity (see section 4.2). Epidural anaesthesia may lead to hypotension and bradycardia. The risk of such effects can be reduced, e.g. by injecting a vasopressor. Hypotension should be treated promptly with a sympathomimetic, repeated as necessary. Adequate facilities should be available for post-operative monitoring and ventilation. Resuscitative equipment, oxygen and a opioid antagonist should be readily available to manage apnoea. NAROPIN is possibly porphyrinogenic and should only be prescribed to patients with acute porphyria when no safer alternative is available. Appropriate precautions should be taken in the case of vulnerable patients. NAROPIN WITH FENTANYL should be used with caution in patients with severe impairment of pulmonary function because of the possibility of respiratory depression (e.g. chronic obstructive pulmonary disease, patients with decreased respiratory reserve, or any patient with potentially compromised respiration). In such patients, opioids may further decrease respiratory drive and increase airway resistance. Respiratory depression caused by opioid analgesics can be reversed by opioid antagonists. Consult individual product information (nalorphine or naloxone) before employing opioid antagonists. Fentanyl may cause muscle rigidity, particularly involving the muscles of respiration. This effect is related to the dose and speed of injection and may be reduced by slow infusion. It is likely to arise following epidural injection. However, if this effect occurs, it may be managed by the use of assisted or controlled respiration and, if necessary, by administration of a neuromuscular blocking agent compatible with the patient’s condition. Nonepileptic myoclonic movements can occur. Fentanyl should be administered with caution to patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs. Fentanyl may produce bradycardia, which may be treated with atropine; however, it should be used with caution in patients with cardiac bradyarrhythmias. NAROPIN AND FENTANYL Data Sheet Copyright 4 As has been observed with all opioid analgesics, episodes suggestive of Sphincter of Oddi Spasm may occur with fentanyl. Concomitant use of Monoamine Oxidase Inhibitors (MAOIs) Fentanyl is not recommended for use in patients who require the concomitant administration of MAOIs due to the risk of serotonin toxicity (see section 4.5). Concomitant use of Benzodiazepines and other Central Nervous System (CNS) Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of fentanyl with benzodiazepines or other CNS depressants (e.g., non- benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anaesthetics, medicines with antihistamine-sedating actions such as antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of medicine-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid
Load more

Recommended publications
  • Chapter 11 Local Anesthetics
    Chapter LOCAL ANESTHETICS 11 Kenneth Drasner HISTORY MECHANISMS OF ACTION AND FACTORS ocal anesthesia can be defined as loss of sensation in AFFECTING BLOCK L a discrete region of the body caused by disruption of Nerve Conduction impulse generation or propagation. Local anesthesia can Anesthetic Effect and the Active Form of the be produced by various chemical and physical means. Local Anesthetic However, in routine clinical practice, local anesthesia is Sodium Ion Channel State, Anesthetic produced by a narrow class of compounds, and recovery Binding, and Use-Dependent Block is normally spontaneous, predictable, and complete. Critical Role of pH Lipid Solubility Differential Local Anesthetic Blockade Spread of Local Anesthesia after Injection HISTORY PHARMACOKINETICS Cocaine’s systemic toxicity, its irritant properties when Local Anesthetic Vasoactivity placed topically or around nerves, and its substantial Metabolism potential for physical and psychological dependence gene- Vasoconstrictors rated interest in identification of an alternative local 1 ADVERSE EFFECTS anesthetic. Because cocaine was known to be a benzoic Systemic Toxicity acid ester (Fig. 11-1), developmental strategies focused Allergic Reactions on this class of chemical compounds. Although benzo- caine was identified before the turn of the century, its SPECIFIC LOCAL ANESTHETICS poor water solubility restricted its use to topical anesthe- Amino-Esters sia, for which it still finds some limited application in Amino-Amide Local Anesthetics modern clinical practice. The
    [Show full text]
  • Pharmacology for Regional Anaesthesia
    Sign up to receive ATOTW weekly - email [email protected] PHARMACOLOGY FOR REGIONAL ANAESTHESIA ANAESTHESIA TUTORIAL OF THE WEEK 49 26TH MARCH 2007 Dr J. Hyndman Questions 1) List the factors that determine the duration of a local anaesthetic nerve block. 2) How much more potent is bupivocaine when compared to lidocaine? 3) How does the addition of epinephrine increase the duration of a nerve block? 4) What is the maximum recommended dose of: a) Plain lidocaine? b) Lidocaine with epinephrine 1:200 000? 5) What is the recommended dose of a) Clonidine to be added to local anaesthetic solution? b) Sodium bicarbonate? In this section, I will discuss the pharmacology of local anaesthetic agents and then describe the various additives used with these agents. I will also briefly cover the pharmacology of the other drugs commonly used in regional anaesthesia practice. A great number of drugs are used in regional anaesthesia. I am sure no two anaesthetists use exactly the same combinations of drugs. I will emphasise the drugs I use in my own practice but the reader may select a different range of drugs according to his experience and drug availability. The important point is to use the drugs you are familiar with. For the purposes of this discussion, I am going to concentrate on the following drugs: Local anaesthetic agents Lidocaine Prilocaine Bupivacaine Levobupivacaine Ropivacaine Local anaesthetic additives Epinephrine Clonidine Felypressin Sodium bicarbonate Commonly used drugs Midazolam/Temazepam Fentanyl Ephedrine Phenylephrine Atropine Propofol ATOTW 49 Pharmacology for regional anaesthesia 29/03/2007 Page 1 of 6 Sign up to receive ATOTW weekly - email [email protected] Ketamine EMLA cream Ametop gel Naloxone Flumazenil PHARMACOLOGY OF LOCAL ANAESTHETIC DRUGS History In 1860, cocaine was extracted from the leaves of the Erythroxylon coca bush.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,828,437 B2 Sundberg Et Al
    USOO8828437B2 (12) United States Patent (10) Patent No.: US 8,828,437 B2 Sundberg et al. (45) Date of Patent: *Sep. 9, 2014 (54) THERMOGELLING ANAESTHETIC USPC .......................................................... 424/484 COMPOSITIONS (58) Field of Classification Search None (71) Applicant: Pharmanest AB, Solna (SE) See application file for complete search history. (72) Inventors: Mark Sundberg, Arsta (SE); Arne (56) References Cited Brodin, Sodertalje (SE); Nils Kallberg, Taby (SE) U.S. PATENT DOCUMENTS (73) Assignee: Pharmanest AB, Solna (SE) 8,663,688 B2* 3/2014 Fernandez et al. ............ 424/487 2004/O220283 A1 11/2004 Zhang et al. 2005/0O27.019 A1 2/2005 Zhang et al. (*) Notice: Subject to any disclaimer, the term of this 2007/0298.005 A1 12, 2007 Thibault patent is extended or adjusted under 35 2008. O15421.0 A1 6/2008 Jordan et al. U.S.C. 154(b) by 0 days. 2012fO294907 A1 11/2012 Zhang et al. This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS AU 2006201233 B2 10, 2007 (21) Appl. No.: 14/172,794 EP O517160 A1 12, 1992 EP 1629852 A2 3, 2006 (22) Filed: Feb. 4, 2014 KR 2002OO13248 A 2, 2002 (65) Prior Publication Data (Continued) OTHER PUBLICATIONS US 2014/O155.434 A1 Jun. 5, 2014 Written Opinion, Intellectual Property Office of Singapore, from the Related U.S. Application Data corresponding Singapore Application No. 201206824-3, Jul. 19. (63) Continuation of application No. 13/638.511, filed as 2013. application No. PCT/EP2011/055009 on Mar. 31, Notification of First Office Action, China Intellectual Property 2011. Office, from the corresponding Chinese Application No.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Delivery System for Mefenamic Acid Based on the Nanocarrier Layered
    Materials Science and Engineering C 58 (2016) 629–638 Contents lists available at ScienceDirect Materials Science and Engineering C journal homepage: www.elsevier.com/locate/msec Delivery system for mefenamic acid based on the nanocarrier layered double hydroxide: Physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential Vanessa R.R. Cunha a, Viviane A. Guilherme b,EneidadePaulab, Daniele R. de Araujo b,c, Renan O. Silva d, Jand V.R. Medeiros d, José R.S.A. Leite d, Philippe A.D. Petersen e, Marianna Foldvari f, Helena M. Petrilli e, Vera R.L. Constantino a,⁎ a Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, USP, Av. Prof. Lineu Prestes 748, 05508-000 São Paulo, São Paulo, Brazil b Departamento de Bioquímica, Instituto de Biologia, Universidade Estadual de Campinas, 13083-970, Campinas, São Paulo, Brazil c Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, 09210-170 Santo André, São Paulo, Brazil d Núcleo de Pesquisa em Biodiversidade e Biotecnologia, BIOTEC, Campus de Parnaíba, Universidade Federal do Piauí, UFPI, 64202020 Parnaíba, Piauí, Brazil e Departamento de Física dos Materiais e Mecânica, Instituto de Física, Universidade de São Paulo, USP, 05315-970 São Paulo, São Paulo, Brazil f School of Pharmacy, University of Waterloo, N2L 3G1 Waterloo, Ontario, Canada article info abstract Article history: Purpose: The anionic form of the drug mefenamic acid intercalated into the nanocarrier layered double hydroxide Received 7 June 2015 (LDH-Mef) was evaluated by anti-inflammatory and antinociceptive assays. Received in revised form 7 August 2015 Methods: The LDH-Mef material was characterized by a set of physicochemical techniques, which was supported Accepted 21 August 2015 by Density Functional Theory calculations.
    [Show full text]
  • A Brief History Behind the Most Used Local Anesthetics
    Tetrahedron xxx (xxxx) xxx Contents lists available at ScienceDirect Tetrahedron journal homepage: www.elsevier.com/locate/tet Tetrahedron report XXX A brief history behind the most used local anesthetics * Marco M. Bezerra, Raquel A.C. Leao,~ Leandro S.M. Miranda, Rodrigo O.M.A. de Souza Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, 21941-909, Brazil article info abstract Article history: The chemistry behind the discovery of local anesthetics is a beautiful way of understanding the devel- Received 13 April 2020 opment and improvement of medicinal/organic chemistry protocols towards the synthesis of biologically Received in revised form active molecules. Here in we present a brief history based on the chemistry development of the most 16 September 2020 used local anesthetics trying to draw a line between the first achievements obtained by the use of Accepted 18 September 2020 cocaine until the synthesis of the mepivacaine analogs nowadays. Available online xxx © 2020 Elsevier Ltd. All rights reserved. Keywords: Anesthetics Medicinal chemistry Organic synthesis Mepivacaíne Contents 1. Introduction . ............................. 00 1.1. Pain and anesthesia . ............................................... 00 1.2. Ancient techniques to achieve anesthesia . ............................... 00 1.3. The objective of this work . .......................................... 00 2. Cocaine .............................................................................................. ............................
    [Show full text]
  • Original Article Lidocaine May Contribute to General Anesthesia by Different Mechanisms in Mammalian Central Nervous System
    Int J Clin Exp Med 2017;10(9):13433-13439 www.ijcem.com /ISSN:1940-5901/IJCEM0049799 Original Article Lidocaine may contribute to general anesthesia by different mechanisms in mammalian central nervous system Mingyang Shi1, Guangbo Xie1,2, Xiaoshuai Fan3, Weidong Pan3, Xiaoshuang Zhou3, Jingbo Yuan3, Zeyi Chen3, Guo Chen3 1Department of Biotechnology, School of Life Science and Technology, University of Electronic Science and Tech- nology of China, Chengdu, China; 2Center for Informational Biology, University of Electronic Science and Technol- ogy of China, Chengdu, China; 3Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China Received October 27, 2016; Accepted June 6, 2017; Epub September 15, 2017; Published September 30, 2017 Abstract: Background: Systemic administration of local anesthetics can produce systemic actions, but the details of these actions and mechanisms are still unclear. We evaluated the systemic actions of three local anesthetics and their underlying mechanisms in this study. Methods: Lidocaine, bupivacaine and ropivacaine were injected into C57BL/6 mice through tail vein, alone or together with hyperpolarization-activated cyclic nucleotide-gated (HCN) channels blocker ZD 7288 or N-methyl-D-aspartic acid (NMDA) receptor blocker MK-801, and hypnotic actions of these local anesthetics, were evaluated by the length of loss of righting reflex (LORR). Results: All of these three lo- cal anesthetics directly produced hypnotic actions with half effective dose (ED50) of 19.0±2.4, 4.3±0.2 and 4.2±0.4 mg/kg. The effects of lidocaine on LORR were enhanced by ZD 7288, ED50 from 19.0±2.4 mg/kg to 14.1±1.0 mg/ kg (P<0.01) or to 13.1±0.8 mg/kg (P<0.01) by MK-801, respectively.
    [Show full text]
  • Interventions for Relieving Pain Associated with Panretinal
    Eye (2006) 20, 712–719 & 2006 Nature Publishing Group All rights reserved 0950-222X/06 $30.00 www.nature.com/eye 1 2 1 1 CLINICAL STUDY Interventions W-C Wu , K-H Hsu , T-L Chen , Y-S Hwang , K-K Lin1, L-M Li1, C-P Shih2 and C-C Lai1 for relieving pain associated with panretinal photocoagulation: a prospective randomized trial Abstract mefenamic acid, and acetaminophen (either alone or in combination with each other) are Purpose To evaluate the efficacy of pain relief not effective in preventing PRP treatment- by oral diazepam, acetaminophen, mefenamic associated pain. Intramuscular injection of 1Department of acid, intramuscular ketorolac tromethamine, ketorolac tromethamine is also not effective in Ophthalmology, Chang and peribulbar anaesthesia in panretinal reducing PRP-associated pain. Gung Memorial Hospital, photocoagulation (PRP). Eye (2006) 20, 712–719. doi:10.1038/sj.eye.6701989; Taoyuan, Taiwan Methods A total of 220 patients with published online 8 July 2005 proliferative diabetic retinopathy requiring 2The Department of Business Administration, PRP treatment were enrolled in this study. Keywords: peribulbar anesthesia; pain; Chang Gung University, Before laser treatment, the patients were panretinal photocoagulation Taoyuan, Taiwan allocated randomly to one of eight groups: group 1: diazepam (n ¼ 22), group 2: Introduction Correspondence: C-C Lai, acetaminophen (n ¼ 21), group 3: mefenamic Department of acid (n ¼ 21), group 4: diazepam and Panretinal photocoagulation (PRP) is an Ophthalmology, Chang Gung Memorial Hospital, acetaminophen (n ¼ 22), group 5: diazepam effective treatment in reducing severe visual 5 Fu-Hsin St, Kwei-Shan, and mefenamic acid (n ¼ 22), group 6: loss in patients with proliferative diabetic 333, Taoyuan, peribulbar anaesthesia with lidocaine (n ¼ 23), retinopathy (PDR).
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Small Dose of Midazolam Added to Fentanyl-Ropivacaine for Patient Controlled Epidural Analgesia After Subtotal Gastrectomy
    Anesth Pain Med 2008; 3: 22～26 ￭임상연구￭ Small Dose of Midazolam Added to Fentanyl-Ropivacaine for Patient Controlled Epidural Analgesia after Subtotal Gastrectomy Department of Anesthesiology and Pain Medicine, Kyungpook National University School of Medicine, Daegu, Korea Kyunghwa Kwak, M.D., Sioh Kim, M.D., Younghoon Jeon, M.D., Jeongwon Suh, M.D., Youngsoo Kim, M.D., Jaehyun Ha, M.D., and Soohyun Lee, M.D. Background: Midazolam has been reported to have a spinally addition, intrathecal co--administration of midazolam and fentanyl mediated antinociceptive effect. In this randomized, double-blind produced better analgesia than either drug alone without increa- study, we evaluated whether a small dose of midazolam added to sing side effect.7) Therefore, we hypothesized that the addition fentanyl-ropivacaine mixture for PCEA (patient controlled epidural analgesia) improves epidural analgesia in patients underwent of small dose of midazolam into opioid-local anesthetic for elective subtotal gastrectomy. PCEA (patient controlled epidural analgesia) could provide Methods: Forty five patients, ASA physical status I and II, under- better postoperative analgesia. Therefore, this prospective, going subtotal gastrectomy were randomly allocated to receive 0.2% ropivacaine mixed with fentanyl 4μg/ml or 0.2% ropivacaine mixed randomized, double-blind, controlled trial was designed to with fentanyl 4μg/ml and midazolam 0.2 mg/ml. The infusion rate evaluate the analgesic efficacy and side effect of midazolam was set to deliver 4 ml/hr of the study solution, with a bolus of 2 added to fentanyl-ropivacaine for PCEA in patients undergoing ml per demand and a 20 minutes lockout time. elective subtotal gastrectomy.
    [Show full text]